Orexo starts clinical study of nasal rescue medication – challenging established market

Allergy firm ALK could face new competition on the market for the emergency treatment of allergic reactions, as the Swedish biotech firm will test its nasal candidate against today’s first-line, intramuscular injection treatments.
Nikolaj Sørensen, CEO of Orexo | Photo: Orexo / PR
Nikolaj Sørensen, CEO of Orexo | Photo: Orexo / PR
by christian bundgaard, translated by daniel pedersen

Swedish biotech firm Orexo is ready to enter the clinical stage with a nasal candidate, OX640, for the emergency treatment of allergic reactions, which includes anaphylaxis, a company press release has announced.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading